S&P 500LLY(USD1156.73-1.52%)UNH(USD389.41-0.90%)MRK(USD147.76-0.40%)PFE(USD28.46+1.79%)
11 min read | September 01, 2026 04:15 AM PDT | By
Anmol Khazanchi
Google News:
Is NextEra Energy (NYSE:NEE) Riding The AI Power-Demand Wave?
Is Duke Energy (NYSE:DUK) Positioned For The Power-Demand Boom?
Is Southern Company (NYSE:SO) A Core Name In The Power-Demand Era?
Is Dominion Energy (NYSE:D) At The Heart Of The Data-Center Boom?
Make Kalkine Media
My Trusted Source
Highlights
- A once-daily oral obesity pill met late-stage trial goals, triggering global regulatory filings.
- A metabolic franchise sits at the center of surging weight-management demand.
- An oral option could widen access beyond injectable incretin medicines.
Eli Lilly (NYSE:LLY)HealthcareEli Lilly and Company (NYSE:LLY)1156.73
USD-17.8801.522%Last Updated at: 2026-08-31T20:26:00Z
drew intense attention as its once-daily oral obesity pill met the goals of a late-stage trial, triggering a wave of global regulatory filings and reinforcing the enterprise’s standing at the center of the metabolic-medicine boom. The result landed amid a broad healthcare rally sparked by clinical-trial momentum across the sector, and it added fresh weight to a franchise that has become one of the defining growth stories in modern medicine.
The Trial Result in Focus
The immediate driver was a successful late-stage study of the enterprise’s oral incretin medicine, which met its primary and key secondary goals and cleared the path for regulatory submissions around the world. A separate maintenance study showed the pill helped people sustain <a href="https://healthylife7.com/kelly-osbourne-breaks-silence-on-dramatic-weight-loss-i-wasnt-well/" title="Kelly Osbourne breaks silence on dramatic weight loss: 'I wasn't well'”>weight loss after switching from injectable therapy, broadening the evidence base for an oral option. Those results matter because an effective pill could reach far more people than injectables, which require refrigeration, needles, and complex manufacturing. The trial success reinforced the enterprise’s front-runner position in a rapidly expanding treatment category.
A Metabolic Powerhouse
The enterprise has built one of the most valuable franchises in medicine around incretin therapies that treat diabetes and obesity. Its injectable medicines transformed the treatment of both conditions, driving explosive demand and reshaping the enterprise’s revenue base. The oral pill extends that franchise into a form that could reach a vastly larger population, from patients wary of injections to markets where cold-chain distribution is difficult. That metabolic engine has propelled the enterprise to the front of the pharmaceutical sector, and the trial success deepened its lead in a category with enormous and still-growing demand.
Why an Oral Option Matters
An effective oral incretin medicine could reshape the treatment landscape. Injectable therapies, while highly effective, face constraints tied to manufacturing complexity, cold-chain logistics, and patient reluctance around needles. A once-daily pill sidesteps many of those hurdles, easing production and widening access across primary care and global markets. The enterprise has moved to build inventory of the medicine ahead of anticipated demand, aiming to avoid the shortages that constrained earlier incretin launches. That readiness underscores the scale of demand the enterprise expects and its determination to serve a market it helped create.
The Obesity Demand Wave
Demand for weight-management medicines has surged into one of the defining themes in healthcare. Rising rates of obesity and diabetes across the developed world, combined with growing recognition of the broader health benefits of these therapies, have driven demand well beyond initial expectations. Research increasingly points to benefits extending to heart and kidney health, expanding the case for wider use. That demand wave has lifted the entire metabolic-medicine space, and the enterprise sits at its center, with the oral pill positioned to extend the reach of these therapies into everyday primary care.
Beyond Metabolic Medicine
While metabolic therapies anchor the enterprise, its reach extends across oncology, immunology, and neuroscience. The company has advanced medicines for cancer, autoimmune conditions, and Alzheimer’s disease, building a pipeline that spans some of the most challenging areas of medicine. That diversification broadens the enterprise’s foundation beyond the metabolic franchise, spreading its exposure across multiple therapeutic areas. The breadth of the pipeline reflects heavy spending on research and development, a hallmark of the enterprise’s approach as it works to sustain a stream of new medicines across a range of serious conditions.
Market Environment and Rates
The advance unfolded against a shifting rate backdrop, with softer jobs and inflation readings reshaping the debate over borrowing costs ahead of the coming central-bank decision. Healthcare has drawn support as a corner of the market prized for innovation and steady demand, and the sector logged its strongest week since June amid a wave of trial momentum. As capital rotated toward sectors offering dependable growth, pharmaceutical leaders with strong pipelines drew renewed attention. That backdrop amplified the market’s response to the enterprise’s trial success.
Competitive Landscape
The enterprise operates within a pharmaceutical sector populated by giants. Its closest rival in metabolic medicine has pursued its own incretin franchise, intensifying a race that has reshaped the sector. Elsewhere, Pfizer (NYSE:PFE)HealthcarePfizer Inc (NYSE:PFE)28.46
USD+0.5001.788%Last Updated at: 2026-08-31T20:28:00Z
has moved to build an obesity presence through acquisition, Merck (NYSE:MRK)HealthcareMerck & Company Inc (NYSE:MRK)147.76
USD-0.5900.398%Last Updated at: 2026-08-31T20:05:00Z
anchors its franchise in oncology and vaccines, and managed-care leader UnitedHealth Group (NYSE:UNH)HealthcareUnitedHealth Group Incorporated (NYSE:UNH)389.41
USD-3.5400.901%Last Updated at: 2026-08-31T20:15:00Z
sits on the benefits side of healthcare. All move within the same sector currents when innovation headlines shift sentiment, yet the enterprise stands apart for its commanding position in the metabolic-medicine category driving so much of the sector’s growth.
Operational Focus
Management has centered its message on scaling manufacturing, advancing its pipeline, and expanding access to its metabolic medicines. Building production capacity for both injectable and oral incretin therapies has taken priority, as the enterprise races to meet demand and avoid shortages. Heavy spending on research and development underpins a broad pipeline spanning oncology, immunology, and neuroscience. That focus on capacity and innovation reflects the scale of the demand the enterprise faces and its determination to sustain a lead across the metabolic category while broadening its reach into other therapeutic areas.
Industry Challenges
Challenges remain material. Drug development is costly and uncertain, and even late-stage medicines can stumble in regulatory review or real-world use. Manufacturing incretin therapies at the scale demand requires has strained capacity across the sector, and pricing scrutiny weighs on the entire pharmaceutical space. Competition in metabolic medicine is intensifying as rivals advance their own candidates, and patent timelines eventually expose blockbuster medicines to generic competition. Regulatory and reimbursement dynamics add further variables. These headwinds frame why manufacturing capacity and pipeline depth remain central to the enterprise’s approach.
Broader Market Relevance
A member of the S&P 500, the enterprise trades as a bellwether for the pharmaceutical sector and for the metabolic-medicine theme reshaping healthcare. Its moves often signal shifting sentiment across the space, drawing attention whenever its franchise advances or faces new competition. The current stretch, with its oral pill clearing late-stage trials, has kept the stock at the center of the healthcare story. Within the wider universe of Healthcare Stocks, the enterprise stands out for its commanding metabolic franchise and its broad pipeline across some of medicine’s most challenging conditions.
Manufacturing at Massive Scale
Meeting demand for its metabolic medicines has required the enterprise to build manufacturing capacity at massive scale. Incretin therapies, whether injectable or oral, demand complex production, and earlier launches across the sector were constrained by shortages when demand outran supply. The enterprise has moved aggressively to expand capacity, building facilities and stockpiling its oral medicine ahead of anticipated demand to avoid the bottlenecks that hampered rivals. That focus on manufacturing reflects the enormous scale of the market and the enterprise’s determination to serve demand it helped create, turning production capacity into a competitive weapon.
The Science of Incretin Medicines
Incretin medicines work by mimicking hormones that regulate blood sugar and appetite, helping patients manage diabetes and achieve significant weight loss. The enterprise’s therapies have proven remarkably effective, transforming the treatment of both conditions and driving demand well beyond early expectations. Research increasingly points to benefits extending to heart and kidney health, broadening the case for wider use. The oral medicine extends that science into a pill form that could reach far more people than injectables. The enterprise’s deep expertise in incretin biology anchors its front-runner position in one of medicine’s most dynamic fields.
A Pipeline Beyond Metabolism
While metabolic medicines anchor the enterprise, its pipeline reaches across oncology, immunology, and neuroscience. The enterprise has advanced treatments for cancer, autoimmune conditions, and Alzheimer’s disease, building a portfolio that spans some of the most challenging areas of medicine. That breadth diversifies the enterprise’s foundation beyond its metabolic franchise, spreading exposure across multiple therapeutic areas. Heavy spending on research and development underpins the pipeline, a hallmark of the enterprise’s approach as it works to sustain a stream of new medicines. The depth of that pipeline reflects an ambition extending well beyond the metabolic category driving its current growth.
Pricing and Access Dynamics
The pricing and access environment shapes the trajectory of metabolic medicines profoundly. Demand has surged, yet questions about affordability and coverage influence how widely the therapies reach patients. The enterprise has worked to expand access while navigating the reimbursement dynamics that govern demand across health systems. An effective oral medicine could ease some access barriers by simplifying distribution and lowering certain costs relative to injectables. Managing pricing and access has become central to the enterprise’s strategy, as it balances serving enormous demand with navigating the complex systems that determine how medicines reach the people who need them.
Competition in Metabolic Medicine
Competition in metabolic medicine has intensified sharply as rivals advance their own incretin candidates. The enterprise’s closest competitor has built a substantial franchise of its own, and the race between the two has reshaped the pharmaceutical sector. Newer entrants are pursuing next-generation therapies aimed at greater efficacy or convenience. That competitive intensity keeps the enterprise pressing to advance its pipeline, expand manufacturing, and broaden the reach of its medicines. Maintaining a lead in such a dynamic field demands continuous innovation, and the oral medicine’s late-stage success reinforced the enterprise’s standing at the front of a fiercely contested category.
A Defining Growth Story
The metabolic-medicine boom has become one of the defining growth stories in modern healthcare, and the enterprise sits at its center. Rising rates of obesity and diabetes, combined with growing recognition of the broader health benefits of these therapies, have driven demand well beyond initial expectations. The oral medicine positions the enterprise to extend the reach of these treatments into everyday primary care, widening the market further. That growth story has propelled the enterprise to the front of the pharmaceutical sector, tying its trajectory to one of the most powerful demand waves reshaping medicine and the broader healthcare economy.
Global Reach of Metabolic Care
The enterprise has worked to extend its metabolic medicines across global markets, recognizing that obesity and diabetes represent worldwide challenges. Injectable therapies face distribution hurdles in many regions, from cold-chain logistics to limited access, constraints that an oral medicine could ease. Building global manufacturing and distribution capacity has taken priority as the enterprise races to serve demand well beyond its home market. That global ambition reflects the scale of the metabolic-medicine wave, which spans developed and developing economies alike. Extending its franchise worldwide positions the enterprise to capture demand across a market that reaches far beyond any single country.
Widening the Case for Metabolic Medicines
Research has increasingly pointed to benefits of metabolic medicines extending well beyond weight loss and blood-sugar control. Evidence has emerged of advantages for heart and kidney health, broadening the case for wider use across patient populations. Those widening benefits strengthen the demand backdrop for the enterprise’s therapies, supporting expanded use as clinical evidence accumulates. The enterprise has pursued studies to document these broader benefits, aiming to establish its medicines across a growing range of conditions. That expanding body of evidence reinforces the enterprise’s standing at the center of one of medicine’s most dynamic and rapidly growing fields.
A Deepening Lead in a Dynamic Field
The enterprise has worked to deepen its lead across a rapidly evolving field, pressing forward on multiple fronts even as competition intensifies. Advancing next-generation candidates, expanding manufacturing, and broadening the reach of its medicines have all taken priority as the enterprise seeks to stay ahead. Its deep expertise in incretin biology, built over years of research, anchors a front-runner position that rivals struggle to challenge. The oral medicine’s late-stage success reinforced that standing, extending the enterprise’s franchise into a form that could reach far more people. Maintaining a lead in such a dynamic field demands relentless innovation, and the enterprise has channeled heavy research spending toward sustaining its momentum.
Reading the Session
The attention reflected a landmark trial success for an oral obesity pill that could widen access far beyond injectables, a result that plays directly to the enterprise’s front-runner position in metabolic medicine. Whether the momentum extends will hinge on regulatory outcomes, manufacturing execution, and the pace of competition, yet the enterprise’s commanding franchise and deep pipeline leave it closely tied to one of the defining growth themes in healthcare. The general information here is provided for reference only and does not constitute financial advice; readers should conduct independent research before making any decisions related to the healthcare sector or the names discussed.
To keep reading, please log in to your account, create a free account, or simply fill out the form below
`;
$(document).find(“#signup_form button[type=’submit’]”).closest(“button”).before(htmlMsg);
setTimeout(() => {
$(“.errorDiv”).fadeOut(300, function () { $(this).remove(); });
}, 3000);
}
jQuery.validator.addMethod(“validName”, function(value, element) {
value = value.trim();
return this.optional(element) || /^(?=(?:.*[A-Za-z]){2,})[A-Za-z]+(?: [A-Za-z]+)*$/.test(value);
}, “Please enter at least 2 letters (letters and single spaces only).”);
function updateResendOtpTimer() {
if (countdown > 0) {
countdown–;
$(“#timer”).text(countdown + “s”);
} else {
clearInterval(timer);
countdown = 30;
otpSent = false;
$(“#resendOtpText”).hide();
$(“#sendOtpLink”).show();
}
}
function sendOtp() {
const phoneInputVal = $(document).find(“#lead_phone”).val().trim();
const dialCode = iti.getSelectedCountryData().dialCode;
const allowedCountries = [“44”, “61”, “1”, “91”, “64”];
if (!phoneInputVal) return showMessage(“error”, “Please enter a mobile number.”);
if (!iti.isValidNumber()) return showMessage(“error”, “Please enter a valid mobile number.”);
if (!allowedCountries.includes(dialCode)) return showMessage(“error”, “OTP is only available for “+ [“au”,”gb”,”ca”,”nz”,”us”,”in”,”uk”]);
if(!otpSent){
$(document).find(“#lead_otp”).val(“”);
}
const phoneNumber = dialCode + phoneInputVal;
request_id = $(document).find(“#ref_id”).val() || ”;
otpSent = true;
$(document).find(“#sendOtpLink”).hide();
$(document).find(“#resendOtpText”).show();
//$(document).find(“.otp-form-group”).hide();
$.ajax({
url: “https://kalkinemedia.com/a/verification”,
type: ‘POST’,
data: { phone_number: phoneNumber, request_id },
headers: { ‘X-CSRF-TOKEN’: ‘jo0swfbovrDUHtioaZKpAMn2zCC3NvM2WEKoiK0D’ },
success: function (response) {
if (response.status === “success”) {
showMessage(“success”, response.message);
//$(document).find(“.otp-form-group”).show();
if ($(document).find(“#ref_id”).length) {
$(document).find(“#ref_id”).val(response.request_id);
} else {
$(”).attr({
type: ‘hidden’,
id: ‘ref_id’,
name: ‘ref_id’,
value: response.request_id
}).appendTo(‘#signup_form’);
}
countdown = 30;
timer = setInterval(updateResendOtpTimer, 1000);
} else {
otpSent = false;
showMessage(“error”, response.message);
$(document).find(“#resendOtpText”).hide();
$(document).find(“#sendOtpLink”).show();
}
},
error: function () {
otpSent = false;
showMessage(“error”, “An error occurred. Please try again.”);
$(document).find(“#resendOtpText”).hide();
$(document).find(“#sendOtpLink”).show();
}
});
}
function verifyOtp() {
$(document).find(“div.otp-form-group div.spinner-border”).removeClass(“d-none”);
// $(document).find(“div.otp-form-group span#verifyOtpLink”).addClass(“d-none”);
$.ajax({
url: “https://kalkinemedia.com/a/verificationChecks”,
type: ‘POST’,
data: {
request_id: $(document).find(“#ref_id”).val(),
code: $(document).find(“#lead_otp”).val()
},
headers: {
‘X-CSRF-TOKEN’: ‘jo0swfbovrDUHtioaZKpAMn2zCC3NvM2WEKoiK0D’
},
success: function(response) {
$(document).find(“div.otp-form-group div.spinner-border”).addClass(“d-none”);
if (response.status === “success”) {
otpVerified = true;
showMessage(“success”, response.message);
$(document).find(“#lead_otp”).prop(“disabled”, true);
// $(document).find(“#signup_form button”).removeClass(“d-none”)
setTimeout(() => toggleReadNowButton(), 0);
// if($(“#hotstock_checkbox”).is(“:checked”)){
// $(document).find(“#signup_form button[type=’submit’]”).prop(“disabled”, false);
// }else{
// $(document).find(“#signup_form button[type=’submit’]”).prop(“disabled”, true);
// }
$(document).find(“#sendOtpLink”).addClass(“d-none”);
$(document).find(“#resendOtpText”).hide();
$(document).find(“#verifyOtpLink”).addClass(“d-none”);
$(document).find(“#successBadge”).removeClass(“d-none”);
} else {
otpVerified = false;
showMessage(“error”, response.message);
setTimeout(() => toggleReadNowButton(), 0);
// $(document).find(“#signup_form button[type=’submit’]”).prop(“disabled”, true);
// $(document).find(“#verifyOtpLink”).removeClass(“d-none”);
}
$(document).find(“#lead_otp”).prop(“disabled”, otpVerified);
},
error: function(xhr, status, error) {
$(document).find(“div.otp-form-group div.spinner-border”).addClass(“d-none”);
showMessage(“error”, error.message);
// $(document).find(“#verifyOtpLink”).removeClass(“d-none”);
$(document).find(“#signup_form button[type=’submit’]”).prop(“disabled”, true);
}
});
}
$(document).find(“#sendOtpLink”).on(“click”, sendOtp);
$(document).on(“input”, “#lead_otp”, function () {
const otp = $(this).val();
if (otp.length === 6) {
verifyOtp();
}
});
// $(document).find(“#verifyOtpLink”).on(“click”, verifyOtp);
function toggleSendOtpButton() {
// if (!iti) return;
const name = $(“#lead_name”).val().trim();
const email = $(“#lead_email”).val().trim();
const phone = $(“#lead_phone”).val().trim();
// const checkbox = $(“#hotstock_checkbox”).is(“:checked”);
const isNameValid = name.length >= 2 && /^[a-zA-Zs]+$/.test(name);
// Validate email: basic email format
const isEmailValid = /^[a-zA-Z0-9._%+-]+@[a-zA-Z0-9.-]+.[a-zA-Z]{2,}$/.test(email);
// Validate phone using intlTelInput
const isPhoneValid = iti && iti.isValidNumber();
// Checkbox validation: must be checked
// const isCheckboxChecked = checkbox;
// If all fields are valid, enable the OTP button
if (isNameValid && isEmailValid && isPhoneValid) {
$(document).find(“#sendOtpLink”).css({“opacity”:”1″, “pointer-events”:”auto”});
} else {
$(document).find(“#sendOtpLink”).css({“opacity”:”0.5″, “pointer-events”:”none”});
}
// const formValid = $(“#signup_form”).valid();
//const phoneValid = iti.isValidNumber();
//if (formValid && phoneValid) {
// $(document).find(“#sendOtpLink”).css({“opacity”:”1″,”pointer-events”:”auto”});
//$(document).find(“#sendOtpLink”).show();
//} else {
// $(document).find(“#sendOtpLink”).css({“opacity”:”0.5″,”pointer-events”:”none”});
//$(document).find(“#sendOtpLink”).hide();
// }
}
function toggleReadNowButton(){
const name = $(“#lead_name”).val().trim();
const email = $(“#lead_email”).val().trim();
const phone = $(“#lead_phone”).val().trim();
const isNameValid = name.length >= 2 && /^[a-zA-Zs]+$/.test(name);
const isEmailValid = /^[a-zA-Z0-9._%+-]+@[a-zA-Z0-9.-]+.[a-zA-Z]{2,}$/.test(email);
const isPhoneValid = iti && iti.isValidNumber();
checkbox = $(“#hotstock_checkbox”).is(“:checked”);
const isCheckboxChecked = checkbox;
if (isNameValid && isEmailValid && isPhoneValid && isCheckboxChecked && otpVerified) {
$(document).find(“#signup_form button[type=’submit’]”).prop(“disabled”, false);
}else{
$(document).find(“#signup_form button[type=’submit’]”).prop(“disabled”, true);
}
}
$(“#signup_form input”).on(“change”, function () {
setTimeout(() => toggleSendOtpButton(), 0);
});
$(“#lead_name”).on(‘input’, function() {
this.value = this.value.replace(/s{2,}/g, ‘ ‘);
this.value = this.value.replace(/[.]/g, ”);
$(this).valid();
toggleSendOtpButton();
});
$(“#lead_email”).on(‘input’, function() {
this.value = this.value.replace(/s/g, ”);
});
if(enableOTPJS){
$(“#signup_form input, #signup_form select”).on(“change”, function () {
setTimeout(() => toggleReadNowButton(), 0);
});
}
$(“#signup_form”).validate({
errorPlacement: function(error, element) {
//element.addClass(‘is-invalid’);
//$(element).siblings(‘.error’).remove();
//if ($(“.is-invalid”).length === 1) {
// error.appendTo(element.parent());
//}
if (element.attr(“name”) == “lead_name”)
error.appendTo(“#errordivname”);
else if (element.attr(“name”) == “lead_email”)
error.appendTo(“#errordivemail”);
else if (element.attr(“name”) == “lead_phone”)
error.appendTo(“#errordivmobile”);
else if (element.attr(“name”) == “hotstock_checkbox”)
error.appendTo(“#errordivcheckbox”);
else if (element.attr(“name”) == “lead_otp”)
error.appendTo(“#errordivotp”);
},
success: function(label, element) {
$(element).removeClass(‘is-invalid’);
label.remove();
},
rules: {
lead_name: {
required: true,
minlength: 2,
maxlength:50,
validName:true
},
lead_phone: {
intlTelNumber: true,
required: true,
number: true,
// validatePhone: true,
maxlength:12
},
lead_email: {
required: true,
email: true,
emailPattern: true
},
hotstock_checkbox: {
required: true,
},
lead_otp: {
required: function() {
// var selectedCountry = iti.getSelectedCountryData();
// return selectedCountry.iso2 === ‘gb’;
var selectedCountry = iti.getSelectedCountryData();
return selectedCountry.iso2 === ‘gb’ || selectedCountry.iso2 === ‘au’ || selectedCountry.iso2 === ‘ca’ || selectedCountry.iso2 === ‘us’;
},
minlength: 6,
maxlength: 6,
digits: true
},
},
onkeyup: function(element) {
this.element(element);
setTimeout(() => toggleSendOtpButton(), 0);
},
onfocusout: function(element) {
this.element(element);
setTimeout(() => toggleSendOtpButton(), 0);
},
messages: {
lead_name: {
required: ‘Please enter valid name.’,
minlength: ‘Name must be at least 4 characters long.’
},
lead_email: {
required: ‘Please enter a valid email address’,
email: ‘Please enter a valid email address (e.g., abc@gmail.com)’,
emailPattern: ‘Please enter a valid email address (e.g., abc@gmail.com)’
},
lead_phone: {
required: ‘Please enter valid mobile number.’
},
hotstock_checkbox: {
required: ‘Please read our Terms and Conditions.’
},
lead_otp: {
required: ‘Valid OTP is required that you’ve received on your number.’
},
},
submitHandler: function(form) {
event.preventDefault();
var navigate_url = $(“.navigate_url”).val();
$(“#signup_form”).find(‘:submit’).html(‘ Loading…’).prop(‘disabled’,true);
// var countryCode = $(“#signup_form”).find(‘div.iti__selected-dial-code’).html()
var selectedCountryData = iti.getSelectedCountryData();
var countryCode = selectedCountryData.iso2;
var countryCode2 = selectedCountryData.dialCode;
$(”).attr({
type: ‘hidden’,
id: ‘countryCode’,
name: ‘countryCode’,
value: countryCode2
}).appendTo(‘#signup_form’);
$(”).attr({
type: ‘hidden’,
id: ‘countryCodeISO’,
name: ‘countryCodeISO’,
value: countryCode
}).appendTo(‘#signup_form’);
var url = “https://kalkinemedia.com/a/checkPhoneNumber”;
url =`${url}/${countryCode2+$(document).find(“#lead_phone”).val()}`
if (enableOTPJS && !otpVerified) {
toast_msg(“OTP Verification required”, ‘error’);
$(“#signup_form”).find(‘:submit’).html(‘Read Now’).prop(‘disabled’, false);
return
}
$.get(url, function(response) {
if (response.status) {
$(”).attr({
type: ‘hidden’,
id: ‘telesignScore’,
name: ‘telesignScore’,
value: response.data.telesign_info ?? “NA”
}).appendTo(‘#signup_form’);
$(”).attr({
type: ‘hidden’,
id: ‘addrScore’,
name: ‘addrScore’,
value: ($(document).find(“#ref_id”).val() !== ” && otpVerified) ? ‘true’: ‘false’
}).appendTo(‘#signup_form’);
// if (response.otp_required && $(document).find(“.otp-form-group”).hasClass(“d-none”)) {
//$(document).find(“.otp-form-group”).removeClass(“d-none”)
// } else {
// $(document).find(“.otp-form-group”).addClass(“d-none”)
// }
$.ajax({
headers: {
‘X-CSRF-TOKEN’: ‘jo0swfbovrDUHtioaZKpAMn2zCC3NvM2WEKoiK0D’
},
type: “POST”,
url: “https://kalkinemedia.com/user/content_block/lead”,
data: $(form).serialize(),
dataType: ‘json’,
success: function(result) {
if (result.status == 1) {
window.location.href = result.redirect_url;
showMessage(“success”, result.message)
} else {
showMessage(“error”, result.message)
$(“#signup_form”).find(‘:submit’).html(
‘Updating’).prop(‘disabled’, false);
}
}
});
}
}).fail(function(jqXHR, textStatus, errorThrown) {
// Handle errors
// console.error(‘Error:’, textStatus, errorThrown);
});
return false;
}
});
});
